Durect Corp DRRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
-
DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update
-
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality
-
DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis
Trading Information
- Previous Close Price
- $0.66
- Day Range
- $0.64–0.69
- 52-Week Range
- $0.47–7.46
- Bid/Ask
- $0.64 / $0.69
- Market Cap
- $19.72 Mil
- Volume/Avg
- 502,240 / 746,821
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.78
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 79
- Website
- https://www.durect.com
Valuation
Metric
|
DRRX
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.31 |
Price/Sales | 1.78 |
Price/Cash Flow | — |
Financial Strength
Metric
|
DRRX
|
---|---|
Quick Ratio | 1.08 |
Current Ratio | 1.19 |
Interest Coverage | −13.14 |
Profitability
Metric
|
DRRX
|
---|---|
Return on Assets (Normalized) | −58.62% |
Return on Equity (Normalized) | −178.96% |
Return on Invested Capital (Normalized) | −81.97% |
Drug Manufacturers - Specialty & Generic Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Ycbt | $83.6 Bil | |
MKKGY
| Merck KGaA ADR | Nkfvys | $67.1 Bil | |
HLN
| Haleon PLC ADR | Vhwq | $37.9 Bil | |
VTRS
| Viatris Inc | Wmyx | $11.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Znlr | $11.4 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Dpjk | $11.3 Bil | |
CTLT
| Catalent Inc | Sljqg | $6.8 Bil | |
PRGO
| Perrigo Co PLC | Vfcg | $4.0 Bil | |
EVO
| Evotec SE ADR | Fxnm | $3.7 Bil | |
CURLF
| Curaleaf Holdings Inc | Zrgt | $3.2 Bil |